Jordi Roca-Ferrer

Jordi Roca-Ferrer

Auto-generated profile, based on publicly available information

Jordi Roca-Ferrer

Immunoallèrgia Respiratòria Clínica i Experimental, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1999 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
CPCésar Picado
César Picado
JFJoan C. Fernandez-Morata
Joan C. Fernandez-Morata
Manel JuanManel Juan
Manel Juan
JRJordi Roca-Ferrer
Jordi Roca-Ferrer
MFMireia Fuentes
Mireia Fuentes
JMJoaquim Mullol
Joaquim Mullol
Exogenous prostaglandin E2 (PGE2) given by inhalation almost completely abrogates aspirin-induced asthma and the accompanying increase in cysteinyl-leukotrienes production. Cyclooxygenase (COX) may be present in cells in both constitutive (COX-1) and inducible (COX-2) forms. To increase the production of the potentially protective endogenous PGE2, COX-2 should be upregulated. We hypothesize that an abnormal regulation of COX-2 will predispose patients with asthma to develop aspirin-intolerant asthma/rhinitis (AIAR). We therefore examined the expression of COX-2 messenger RNA (mRNA) in healthy nasal mucosa (n = 11) and in nasal polyps from both patients with AIAR (n = 8) and those with aspirin-tolerant asthma/rhinitis (ATAR) (n = 20). After total mRNA extraction, COX-1 and COX-2 mRNA expression were measured using a reverse transcriptase (RT)-semiquantitative PCR technique. Hybrid primers of COX-1 · glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or COX-2 · GAPDH were used to create PCR products that were cloned and used as internal standard controls in the competitive PCR reaction. Results are presented as mean ± standard error of 106 molecules of mRNA/ μ g of total RNA. No differences in COX-1 mRNA expression were found between nasal mucosa and nasal polyps from both patients with ATAR and those with AIAR. However, COX-2 mRNA expression in nasal polyps from the AIAR group (0.38 ± 0.10) was markedly and significantly lower than in polyps from the ATAR group (2.93 ± 0.52, sevenfold, p < 0.0001) and nasal mucosa (2.10 ± 0.54, sixfold, p < 0.01). These findings suggest that an inadequate COX-2 regulation may be involved in AIAR.

1 October 2002 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
LPLaura Pujols
Laura Pujols
JMJoaquim Mullol
Joaquim Mullol
JRJordi Roca-Ferrer
Jordi Roca-Ferrer
ATAlfons Torrego
Alfons Torrego
AXAntoni Xaubet
Antoni Xaubet
CPCésar Picado
César Picado
Alternative splicing of the human glucocorticoid receptor (GR) primary transcript generates two protein isoforms: GR-α and GR-β. We investigated the expression of both GR isoforms in healthy human cells and tissues. GR-α mRNA abundance (×106 cDNA copies/μg total RNA) was as follows: brain (3.83 ± 0.80) > skeletal muscle > macrophages > lung > kidney > liver > heart > eosinophils > peripheral blood mononuclear cells (PBMCs) > nasal mucosa > neutrophils > colon (0.33 ± 0.04). GR-β mRNA was much less expressed than GR-α mRNA. Its abundance (×103 cDNA copies/μg total RNA) was as follows: eosinophils (1.55 ± 0.58) > PBMCs > liver ≥ skeletal muscle > kidney > macrophages > lung > neutrophils > brain ≥ nasal mucosa > heart (0.15 ± 0.08). GR-β mRNA was not found in colon. While GR-α protein was detected in all cells and tissues, GR-β was not detected in any specimen. Our results suggest that, in physiological conditions, the default splicing pathway is the one leading to GR-α. The alternative splicing event leading to GR-β is minimally activated.

1 July 2011 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
JRJordi Roca-Ferrer
Jordi Roca-Ferrer
FGFrancesc J. Garcia-Garcia
Francesc J. Garcia-Garcia
JCJavier Pereda Cervera
Javier Pereda Cervera
MPMaria Perez-Gonzalez
Maria Perez-Gonzalez
LPLaura Pujols
Laura Pujols
CPCesar Picado
Cesar Picado

2 March 2006 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
AMAsunción Martinez
Asunción Martinez
CDC. DeBolós
C. DeBolós
MGM. Garrido
M. Garrido
JRJ. Roca‐Ferrer
J. Roca‐Ferrer
CBC. Barranco
C. Barranco
JMJoaquim Mullol
Joaquim Mullol

1 January 2001 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
LPLaura Pujols
Laura Pujols
JMJoaquim Mullol
Joaquim Mullol
MPMaria Pérez
Maria Pérez
JRJordi Roca-Ferrer
Jordi Roca-Ferrer
Manel JuanManel Juan
Manel Juan
CPCésar Picado
César Picado
Two isoforms of the human glucocorticoid receptor (hGR) have been described, hGR α and hGR β. We analyzed the expression and regulation of both hGR isoforms in human respiratory epithelial cells (BEAS-2B, A549, and primary nasal epithelial cells). In BEAS-2B cells, the expression of hGR α messenger RNA (mRNA) was much higher than that of hGR β mRNA. Dexamethasone (DEX) (10−6 M) downregulated hGR α mRNA at 6 and 24 h (55 ± 8 and 58 ± 5% of control, respectively; P < 0.01), whereas it decreased hGR β mRNA only at 6 h (55 ± 7% of control; P < 0.01). Downregulation of hGR α and hGR β mRNAs occurred even in the presence of cycloheximide. Actinomycin-D studies revealed that DEX enhanced the stabilization of hGR α and hGR β messages. hGR α but not hGR β protein was detected in BEAS-2B, A549, and nasal epithelial cells. After 24 h of incubation, 10−6 M DEX decreased the expression of hGR α protein in BEAS-2B, A549, and nasal epithelial cells (16 ± 4, 14 ± 4, and 28 ± 7% of control, respectively; P < 0.01). These results suggest that in respiratory epithelial cells: (1) hGR α is much more expressed than hGR β at both the mRNA and protein levels; (2) hGR α is downregulated by corticosteroids both in cell lines (BEAS-2B, A549) and in nasal primary cells; and (3) transcriptional, post-transcriptional, and post-translational mechanisms appear to be involved in the regulation of hGR expression by corticosteroids.

1 July 1995 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
JMJ. Mullou
J. Mullou
AXA. Xaubet
A. Xaubet
AGAntoni Gaya
Antoni Gaya
JRJ. Roca‐Ferrer
J. Roca‐Ferrer
ELE. López
E. López
CPC. Picado
C. Picado